All In Biotech

Drug Trial Radar · NCT04727424

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Fluvoxamine Plus Budesonide, Fluoxetine Plus Budesonide and Spirulin Platensis, in High Risk Patients With Mild COVID-19

Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 7,819 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

7,819

Planned (sponsor's estimate)

Start

Jan 19, 2021

Primary completion

Jun 1, 2024

Study completion Jul 1, 2024

Sponsor

Lead sponsor
CardresearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cytel Inc.; McMaster University; Fastgrants; Eiger BioPharmaceuticals; RainWater Foundation
First posted
Jan 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a potential anti-inflammatory role of Fluvoxamine, Fluoxetine, Budesonide and Spirulin Platensis in SARS-CoV-2 infections and observational studies have suggested a reduced complications in patients with COVID-19 disease.

Conditions

  • Covid19
  • SARS-Associated Coronavirus

Interventions

  • Spirulin PlatensisDietary supplement

    Two tablets every 12 hours since randomization through day 09 following randomization

  • Budesonide PowderDrug

    One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 09.

  • Fluoxetine 20 MGDrug

    Two Fluoxetine tablets every day starting just after randomization through day 07. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.

  • PlaceboDrug

    Placebo oral tablets (10-day schedule): Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS Placebo Inhalation Therapy: One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days OR Paracetamol (07-day schedule - active comparator): Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm) OR Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in emergency care visits due to the worsening of COVID-19;Time frame: 28 days
  2. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in changing the need for Hospitalization due to COVID-19 progression and related complications, including lower respiratory tract infection (LRTI)Time frame: 28 days
  3. Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in changing SPO2 ≤ 93% after randomizationTime frame: 28 days

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • CARDRESEARCH - Cardiologia Assistencial e de Pesquisa

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • City of Betim

    Betim, Minas Gerais, Brazil · Recruiting

  • City of Brumadinho

    Brumadinho, Minas Gerais, Brazil · Not yet recruiting

  • Hospital e Maternidade Santa Rita

    Contagem, Minas Gerais, Brazil · Recruiting

  • City of Governador Valadares

    Governador Valadares, Minas Gerais, Brazil · Recruiting

  • City of Ibirité

    Ibirité, Minas Gerais, Brazil · Recruiting

  • City of Igarapé

    Igarapé, Minas Gerais, Brazil · Recruiting

  • Centro Universitário FIPMOC

    Montes Claros, Minas Gerais, Brazil · Recruiting

  • City of Nova Lima

    Nova Lima, Minas Gerais, Brazil · Recruiting

  • Universidade Federal de Ouro Preto

    Ouro Preto, Minas Gerais, Brazil · Recruiting

  • City of Santa Luzia

    Santa Luzia, Minas Gerais, Brazil · Recruiting

  • City of Sete Lagoas

    Sete Lagoas, Minas Gerais, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.